SCHEMBL13440560

SCHEMBL13440560

O=c1cc(NC2CC2)c2ccccc2o1

nearest known ligand 0.86

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.86
KDM4E B2RXH2 3/20 0.86
MCHR1 Q99705 3/20 0.61
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
HTT P42858 2/20 0.54
RECQL P46063 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NQO1 P15559 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA9 Q16790 1/20 0.49
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6187519 0.90 LMNA (0.75) LMNAKDM4EMCHR1ALDH1A1HPGD
Hydrochloric Acid SCHEMBL23360443 0.89 LMNA (0.73) LMNAKDM4EMCHR1ALDH1A1HPGD
Hydrochloric Acid SCHEMBL29862517 0.89 LMNA (0.73) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL17847541 0.84 LMNA (0.67) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL19753762 0.83 LMNA (0.65) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL17845025 0.81 MCHR1 (0.64) LMNAKDM4EMCHR1HPGDHTT
SCHEMBL17847506 0.81 MCHR1 (0.67) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL6869205 0.80 KMT5B (0.61) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL6869201 0.80 KMT5B (0.61) LMNAKDM4EMCHR1ALDH1A1HPGD
SCHEMBL17861413 0.80 MCHR1 (0.63) LMNAKDM4EMCHR1HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. 2010-03-18 US disclosed
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. 2010-03-18 US disclosed
WO-2008127274-A2 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF NSUN3, TARBP1, TRMT1 LMNA 2706/4885KDM4E 2676/4885MCHR1 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.